NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=175821&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or […]

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your RCI Hospitality Holdings, Inc. (NASDAQ:RICK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/rci-hospitality-holdings-inc-lawsuit-submission-form?prid=175820&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Transition offers Continued Support of Surelock's Growth in the Secure Storage Industry Outdoor Brands, LLC announced today the finalized sale of Surelock Security Co. to Meyer Distributing Inc. https://mma.prnewswire.com/media/2814888/Outdoor_Brands_Logo.jpg Surelock Security Co. specializes in the design and manufacturing of high-quality safes and secure storage. Surelock Security Co. is further diversifying the Meyer Distributing Inc. portfolio,

Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases, today announced the upcoming presentation of preclinical data for its first-in-class, wild-type-sparing JAK2-JH2/V617F inhibitorZE74-0282at the 67th American Society of Hematology (ASH) Annual Meeting. The company also confirmed plans to initiate first-in-human clinical studies inDecember 2025. https://mma.prnewswire.com/media/2189834/Eilean_Therapeutics_Logo.jpg Background TheJAK2 V617F mutationis

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your Fortinet, Inc. (NASDAQ:FTNT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fortinet-inc-lawsuit-submission-form?prid=175819&wire=1&utm_campaign=2 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

NEW YORK, NY / ACCESS Newswire / November 6, 2025 / If you suffered a loss on your V.F. Corporation (NYSE:VFC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/v-f-corporation-lawsuit-submission-form?prid=175818&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

As regulatory complexity accelerates worldwide, enterprises face a defining challenge: how to manage mounting environmental, social, and governance (ESG) disclosure demands without overwhelming their operations. Across industries, the convergence of artificial intelligence, regulatory technology, and sustainability management is transforming compliance from a cost center into a source of strategic advantage. The New Regulatory Reality Governments

(NYSE MKT:EXOD), OMAHA, Neb., Nov. 06, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital asset holdings of Exodus' corporate treasury, as well as updated user and exchange provider processed volume metrics, as of October 31, 2025: Selected

Exodus Movement, Inc. October 2025 Treasury Update and Monthly Metrics Q3 earnings call premarket Nov. 10; Treasury grows to 2,147 BTC GlobeNewswire November 06, 2025 OMAHA, Neb., Nov. 06, 2025 (GLOBE NEWSWIRE) — Exodus Movement, Inc. (NYSE American: EXOD) (“Exodus” or “the company”), a leading self-custodial cryptocurrency platform, today announced an update to selected digital

Assistive Technology Development, Inc. (ATDev) announced today that it is a subcontractor for the Robotic Assistive Mobility and Manipulation Platform (RAMMP) program, awarded to the University of Pittsburgh under the Advanced Research Projects Agency for Health (ARPA-H) for up to $41 million. https://mma.prnewswire.com/media/2815094/ATDev_TEAM.jpg Led by Principal Investigator Rory Cooper, Ph.D. at University of Pittsburgh, the